Best ASX Biotech Stocks to Invest In
AI-curated Biotech stock ideas for the Australian (ASX) market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
20 picks · prices as of close 2026-10-27
CSL Limited
Global plasma franchise, improving sentiment, and pipeline optionality support valuation recovery.
▸Analyst support and strategic Alentis co-development agreement.
Mesoblast Limited
Commercial Ryoncil growth and regulatory progress create substantial rerating potential.
▸Buy rating, FDA assay approval, and upcoming clinical readouts.
Imricor Medical Systems, Inc.
MRI-guided cardiac ablation platform offers regulatory and international commercial upside.
▸Analyst target upgrade following FDA breakthrough clearance.
Saluda Medical, Inc.
CAP24 commercial rollout expands access to a significant underpenetrated spinal-stimulation market.
▸US commercial launch and speculative-buy analyst coverage.
Neurizon Therapeutics Limited
Clearer FDA pathway and pivotal ALS data provide a major clinical value inflection.
▸Positive FDA regulatory feedback and speculative-buy rating.
Neuren Pharmaceuticals Limited
Commercial neurodevelopment therapies generate recurring revenue and pipeline optionality.
▸Commercial revenue base and analyst target above market price.
Dimerix Limited
Phase 3 kidney-disease program offers a near-term clinical and commercial catalyst.
▸Phase 3 treatment milestone and ongoing clinical development.
Nyrada Inc.
Cardiovascular and brain-injury programs provide multiple clinical catalysts and financing visibility.
▸Positive cash position and PROTECT-MI clinical update.
Actinogen Medical Limited
Alzheimer’s trial topline results could materially re-rate the company if efficacy is demonstrated.
▸Phase 2b/3 XanaMIA topline results expected shortly.
Lumos Diagnostics Holdings Limited
Respiratory-season adoption could accelerate utilisation of its point-of-care diagnostic platform.
▸US respiratory season provides near-term commercial catalyst.
Tetratherix Limited
Multiple FDA clearances and pivotal tissue-spacing progress provide several rerating catalysts.
▸Potential FDA 510(k) clearances and pivotal-trial progress.
EBR Systems, Inc.
US procedure growth for wireless cardiac pacing could strengthen commercial momentum.
▸Expected update on US WiSE procedure volumes.
Vitrafy Life Sciences Limited
Diagnostic platform milestones could drive investor attention and commercial validation.
▸Upcoming clinical and regulatory milestones.
BlinkLab Limited
Digital diagnostic development and healthcare-sector momentum create speculative upside.
▸Upcoming company milestones and sector momentum.
Syntara Limited
Deep valuation discount offers asymmetric upside if clinical execution improves.
▸Large analyst valuation gap despite recent weakness.
OncoSil Medical Limited
Regulatory decision for its targeted radiotherapy platform could unlock substantial value.
▸FDA HDE application review is a major catalyst.
Celtic Therapeutics
CAR-T safety data may validate a differentiated oncology platform and attract partnering interest.
▸Expected Phase 1 glioblastoma safety data.
Sonic Healthcare Limited
Defensive diagnostics exposure and healthcare demand offer lower-risk sector participation.
▸Defensive healthcare exposure with recurring diagnostic demand.
Racura Oncology Ltd
Oncology pipeline optionality and upcoming data provide high-risk, high-reward potential.
▸Clinical pipeline updates remain the primary value catalyst.
Ecofibre Limited
Biotech-derived health products and operational recovery could support a speculative rebound.
▸Potential operational recovery and healthcare-product catalyst.